Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: Biological difference or misclassification?

Oncologist

Volumn 19, Issue 6, 2014, Pages 592-601

  Sighoko, Dominique ^a   Liu, Juxin ^c   Hou, Ningqi ^b   Gustafson, Paul ^d   Huo, Dezheng ^b  

^a Department of Medicine   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Breast neoplasms; Discordance; Estrogen receptor; Metastasis biopsy; Metastatic breast carcinoma; Second primary neoplasm

Indexed keywords

ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN;

ARTICLE; BAYESIAN LEARNING; BREAST CANCER; DATA BASE; HORMONE DETERMINATION; HUMAN; INFORMATION PROCESSING; META ANALYSIS; METASTASIS; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; SECOND CANCER; SENSITIVITY AND SPECIFICITY; BAYES THEOREM; BIOPSY; BREAST NEOPLASMS; FEMALE; METABOLISM; NEOPLASMS, SECOND PRIMARY; PATHOLOGY; TUMOR RECURRENCE;

BAYES THEOREM; BIOPSY; BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; RECEPTORS, PROGESTERONE;

EID: 84901938846     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0427     Document Type: Article

References (59)

1. Wolff AC, Dowsett M. Estrogen receptor: A never ending story? J Clin Oncol 2011;29:2955-2958.
2. Davies C, Godwin J, Gray R et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet 2011; 378:771-784.
3. Coradini D, Oriana S, Mariani L et al. Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumour? Eur J Cancer 1998;34:825-830.
4. Gong Y, Han EY, GuoMet al. Stability of estrogen receptor status in breast carcinoma: A comparison between primary and metastatic tumors with regard to disease course and intervening systemic therapy. Cancer 2011;117:705-713.
5. Huo D, Melkonian S, Rathouz PJ et al. Concordance in histological and biological parameters between first and second primary breast cancers. Cancer 2011;117:907-915.
6. Swain SM, Wilson JW, Mamounas EP et al. Estrogen receptor status of primary breast cancer is predictive ofestrogenreceptor status ofcontralateral breast cancer. J Natl Cancer Inst 2004;96:516-523.
7. Pusztai L, Viale G, Kelly CM et al. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. The Oncologist 2010;15:1164-1168.
8. Carlson RW, Allred DC, Anderson BO et al. Metastatic breast cancer, version 1.2012: Featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10:821-829.
9. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 2008;21(suppl 2):S8-S15.
10. Allison KH. Estrogen receptor expression in breast cancer: We cannot ignore the shades of gray. Am J Clin Pathol 2008;130:853-854.
11. Rhodes A, Jasani B, Barnes DM et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: Interlaboratory variance in the sensitivity ofdetection and evaluation of scoring systems. J Clin Pathol 2000;53:125-130.
12. Rüdiger T, Höfler H, Kreipe HH et al. Quality assurance in immunohistochemistry: Results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol 2002;26:873-882.
13. Goldstein NS, Ferkowicz M, Odish E et al. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol 2003;120:86-92.
14. Surveillance, Epidemiology, and End Results (SEER) Program Research Data (1973-2010), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2014, based on the November 2013 submission. Available at www.seer.cancer.gov.
15. Stroup DF, Berlin JA, Morton SC et al. Metaanalysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-2012.
16. Liedtke C, Broglio K, Moulder S et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009;20:1953-1958.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
18. Gustafson P. Measurement Error and Misclassification in Statistics and Epidemiology: Impacts and Bayesian Adjustments. London, U.K.: Chapman and Hall/CRC, 2003:200.
19. Higgins JP, Thompson SG, Deeks JJ et al. 2003; 327:557-560.
20. Khoury T, Sait S, Hwang H et al. Delay to formalin fixation effect on breast biomarkers. Mod Pathol 2009;22:1457-1467.
21. Rhodes A, Jasani B, Balaton AJ et al. Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. Am J Clin Pathol 2001;115:44-58.
22. Engel KB, Moore HM. Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med 2011;135:537-543.
23. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784-2795.
24. Welsh AW, Moeder CB, Kumar S et al. Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J ClinOncol 2011;29:2978-2984.
25. de Dueñas EM, Hernández AL, Zotano AG et al. Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: Results from the GEICAM 2009-03 ConvertHER study. Breast Cancer Res Treat 2014; 143:507-515.
26. Thompson AM, Jordan LB, Quinlan P et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: The Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res 2010;12:R92.
27. Amir E, Miller N, Geddie W et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012;30:587-592.
28. Hoehn JL, Plotka ED, Dickson KB. Comparison of estrogen receptor levels in primary and regional metastatic carcinoma of the breast. Ann Surg 1979; 190:69-71.
29. Brennan MJ, Donegan WL, Appleby DE. The variability of estrogen receptors in metastatic breast cancer. Am J Surg 1979;137:260-262.
30. Hull DF III, Clark GM, Osborne CK et al. Multiple estrogen receptor assays in human breast cancer. Cancer Res 1983;43:413-416.
31. Holdaway IM, Bowditch JV. Variation in receptor status between primary and metastatic breast cancer. Cancer 1983;52:479-485.
32. Raemaekers JM, Beex LV, Koenders AJ et al. Concordance and discordance of estrogen and progesterone receptor content in sequential biopsies of patients with advanced breast cancer: Relation to survival. Eur J Cancer Clin Oncol 1984;20:1011-1018.
33. Nomura Y, Tashiro H, Shinozuka K. Changes of steroid hormone receptor content by chemotherapy and/or endocrine therapy in advanced breast cancer. Cancer 1985;55:546-551.
34. Kamby C, Rasmussen BB, Kristensen B. Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Br JCancer1989;60:252-257.
35. Spataro V, Price K, Goldhirsch A et al. Sequential estrogen receptor determinations from primary breast cancer and at relapse: Prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group). Ann Oncol 1992;3:733-740.
36. Li BD, Byskosh A, Molteni A et al. Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg Oncol 1994; 57:71-77.
37. Kuukasjarvi T, Kononen J, Helin H et al. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996;14:2584-2589.
38. Shimizu C, Fukutomi T, Tsuda H et al. c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol 2000;73:17-20.
39. Sekido Y, Umemura S, Takekoshi S et al. Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation. Int J Oncol 2003;22:1225-1232.
40. Lower EE, Glass EL, Bradley DA et al. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 2005;90:65-70.
41. Gutierrez MC, Detre S, Johnston S et al. Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005;23:2469-2476.
42. Gomez-Fernandez C, Daneshbod Y, Nassiri M et al. Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer. AmJ Clin Pathol 2008;130: 879-882.
43. Wu JM, Fackler MJ, Halushka MK et al. Heterogeneity of breast cancer metastases: Comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 2008; 14:1938-1946.
44. Broom RJ, Tang PA, Simmons C et al. Changes in estrogen receptor, progesterone receptor and Her- 2/neu status with time: Discordance rates between primary and metastatic breast cancer. Anticancer Res 2009;29:1557-1562.
45. Idirisinghe PK, Thike AA, Cheok PY et al. Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance. Am J Clin Pathol 2010;133:416-429.
46. Hoefnagel LD, van de Vijver MJ, van Slooten HJ et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res 2010;12:R75.
47. Bogina G, Bortesi L, Marconi M et al. Comparison of hormonal receptorand her-2 status between breast primary tumours and relapsing tumours: Clinical implications of progesterone receptor loss. Virchows Arch 2011;459:1-10.
48. Curigliano G, BagnardiV,VialeGet al. Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol 2011;22:2227-2233.
49. Sari E, Guler G, Hayran M et al.Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer. Med Oncol 2011;28:57-63.
50. Nishimura R, Osako T, Okumura Y et al. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: Discordance rates and prognosis. World J Surg Oncol 2011;9:131.
51. Chang HJ, Han SW, Oh DY et al. Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab. Jpn J Clin Oncol 2011;41:593-599.
52. Jensen JD, Knoop A, Ewertz M et al. ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer. Breast Cancer Res Treat 2012;132: 511-521.
53. Montagna E, Bagnardi V, Rotmensz N et al. Breast cancer subtypes and outcome after local and regional relapse. Ann Oncol 2012;23:324-331.
54. Duchnowska R, Dziadziuszko R, Trojanowski T et al. Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain. Breast Cancer Res 2012;14:R119.
55. Lindstrom LS, Karlsson E, Wilking UM et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012;30:2601-2608.
56. Ibrahim T, Farolfi A, Scarpi E et al. Hormonal receptor, human epidermal growth factor receptor- 2, and Ki67 discordance between primary breast cancer and paired metastases: Clinical impact. Oncology 2013;84:150-157.
57. Dieci MV, Barbieri E, Piacentini F et al. Discordance in receptor status between primary andrecurrent breastcancer has aprognostic impact: A single-institution analysis. Ann Oncol 2013;24: 101-108.
58. Aurilio G, Monfardini L, Rizzo S et al. Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. Acta Oncol 2013;52:1649-1656.
59. Curtit E, Nerich V, Mansi L et al. Discordances in estrogen receptor status, progesterone receptor status, andHER2statusbetween primarybreast cancer and metastasis. The Oncologist 2013;18:667-674.